# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Jefferies analyst Dennis Ding maintains Arbutus Biopharma (NASDAQ:ABUS) with a Buy and raises the price target from $5 to $7.
JMP Securities analyst Roy Buchanan maintains Arbutus Biopharma (NASDAQ:ABUS) with a Market Outperform and raises the price ...
With These Organizational Changes And Its Ongoing Cost Management Efforts, The Company Now Expects Its Current Cash, Cash Equiv...
HC Wainwright & Co. analyst Ed Arce reiterates Arbutus Biopharma (NASDAQ:ABUS) with a Buy and maintains $5 price target.
In the HBV003 trial, 67% of participants had HBsAg <10 IU/mL and 19% of participants had undetectable HBsAg when assessed fo...
HC Wainwright & Co. analyst Ed Arce reiterates Arbutus Biopharma (NASDAQ:ABUS) with a Buy and maintains $5 price target.